Biomarkers in Urolithiasis

David E Hinojosa-Gonzalez; Brian H Eisner

doi:10.1016/j.ucl.2022.09.004

Biomarkers in Urolithiasis

Urol Clin North Am. 2023 Feb;50(1):19-29. doi: 10.1016/j.ucl.2022.09.004.

Authors

David E Hinojosa-Gonzalez¹, Brian H Eisner²

Affiliations

¹ Department of Urology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 1102, Boston, MA 02114, USA.
² Department of Urology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 1102, Boston, MA 02114, USA. Electronic address: beisner@mgh.harvard.edu.

PMID: 36424080
DOI: 10.1016/j.ucl.2022.09.004

Abstract

A variety of biomarkers have been studied in the setting of conditions and scenarios related to kidney stone disease. These biomarkers are commonly serum markers, novel urinary proteins, and inflammatory whose use is aimed at providing clinicians with additional information of underlying processes and improving detection and stratification of patients with kidney stones, acute ureteral obstruction, stone passage, and related infectious complications. Their adoption has been limited, and further evidence is required to determine their role in the care of patients with stone disease.

Keywords: Biomarkers; Kidney stones; Nephrolithiasis; Urolithiasis.

Publication types

Review

MeSH terms

Biomarkers
Humans
Kidney Calculi* / diagnosis
Ureter*
Ureteral Calculi*
Urolithiasis* / diagnosis

Substances

Biomarkers